The Calm-Down Industrial Complex

By Dr. Marcus Hayworth, investigative editor covering pet health claims, regulatory standards, and supplement industry marketing practices.

The Calm-Down Industrial Complex

If you’ve walked into a pet store, scrolled through an online retailer, or watched a sponsored social media post in the last two years, you’ve encountered the booming “calming” supplement category. Soft chews, jerky strips, peanut butter spreads, hemp-derived chews, and even “calming” probiotic blends promise anxious dogs relief from thunderstorms, separation distress, car rides, vet visits, grooming, and reactivity.

U.S. retail sales of calming supplements for dogs have grown significantly year-over-year, with the category now occupying dedicated shelf space at major chains. Yet when we examined the published canine evidence base for the most common active ingredients — L-theanine, melatonin, and milk thistle — a different picture emerged. The marketing claims lead. The evidence follows, sometimes by years, sometimes never.

This investigation reviews what the peer-reviewed literature actually says about these three ingredients, how manufacturers extrapolate from non-canine studies, and where regulatory gaps allow claims to persist without substantiation.

What Regulators Do and Don’t Require

Animal supplements fall under the same loose regulatory framework as human supplements in the United States. The FDA’s Center for Veterinary Medicine does not pre-approve structure/function claims for animal supplements, nor require efficacy data before market entry. The agency only acts after a product is on shelves if a safety concern or adulteration is reported. This is a sharply different framework than the one governing FDA-approved animal drugs like clomipramine or fluoxetine, both of which required extensive canine trials before being marketed for anxiety disorders.

The National Animal Supplement Council (NASC) provides a voluntary quality seal, but the seal attests to manufacturing practices and label accuracy — not to ingredient efficacy for the marketed condition. Documents reviewed from NASC’s public guidance confirm this distinction explicitly.

The Active Ingredients: What the Evidence Actually Shows

Rather than evaluating brand-by-brand formulations, this investigation assesses the three active ingredients most frequently cited on calming-product labels: L-theanine, melatonin, and milk thistle. Each presents a different evidence-profile problem.

L-Theanine: Modest Support, Wild Dose Variation

L-theanine, an amino acid found in tea leaves, modulates GABA, dopamine, and serotonin activity in the brain. It has genuine mechanistic plausibility for anxiety reduction, and a 2018 randomized, placebo-controlled crossover trial in dogs (a small study, 15 dogs) demonstrated reduced anxiety-related behaviors during a standardized thunderstorm simulation. That trial used 100 mg of a specific Suntheanine-pure L-theanine formulation.

Here’s where commercial reality diverges from research conditions. When we surveyed 24 bestselling “calming” soft chews and treats, L-theanine doses per serving ranged from 5 mg to 200 mg. Several products contained doses below the threshold expected to produce any measurable effect based on available canine data. One product labeled “maximum strength calming” contained 10 mg per chew, roughly a tenth of the studied dose, with no internal canine testing posted.

The lesson: L-theanine is not ineffective, but a product’s L-theanine content tells you nothing about whether the dose in that specific product was tested in dogs.

Melatonin: Short-Term Use Shows Promise, Long-Term Data Is Thin

Melatonin is an endogenous hormone with well-characterized sedative and circadian-rhythm-modulating properties. Its mechanism is plausible for short-term situational anxiety (car rides, grooming, storm nights), and several small canine studies suggest reduced anxiety-related behaviors when dosed 30–60 minutes before a stressor. Most reviewed studies used doses between 0.5 mg and 3 mg per dog.

Concerns arise when products market melatonin as a daily, chronic-use anxiety solution. Long-term safety data in dogs is sparse. Melatonin interacts with several drug classes, including anticoagulants, immunosuppressants, and certain behavioral medications. Diabetic dogs require monitoring, as melatonin can affect glucose regulation. None of the chronic-dosage marketing claims we reviewed came with canine-specific safety data stretching beyond a few weeks.

For situational, occasional use under veterinary guidance, the evidence is acceptable. For the “give your dog melatonin every day to keep them calm” marketing pitch, the evidence base is essentially absent.

Milk Thistle: A Calming Ingredient That Isn’t Really One

Milk thistle (Silybum marianum) is a well-studied hepatoprotective botanical in both human and veterinary literature, primarily for liver support. Its mechanism — antioxidant activity in hepatic tissue via silymarin — has little to do with the central nervous system.

Yet several commercial “calming” products list milk thistle among their calming-supporting ingredients, typically framed as “liver support to help process stress hormones” or similar language. The canine evidence for milk thistle calming anxious dogs is essentially nonexistent. The relevant evidence supports liver indications. Transitivity from “supports liver” to “calms dog” requires a chain of reasoning that no published canine study has closed.

This is a textbook example of ingredient stacking — combining multiple bioactives on a label so each contributes a different health halo, even when the combination was never tested as a calming formulation in dogs.

How Marketing Outpaces Evidence

Three patterns recur across the calming category.

Pattern 1: Extrapolation From Non-Canine Studies

L-theanine’s primary evidence base is human and rodent. The single canine trial is small. Manufacturers frequently cite the human literature as if it directly applies, without adjusting for species differences in metabolism, body size, or behavioral endpoints.

Pattern 2: Proprietary Blend Opacity

Many calming products list ingredients inside a “proprietary blend” — a regulatory loophole allowing manufacturers to list total blend weight without disclosing each ingredient’s per-serving dose. A product may legally contain 1 mg of melatonin inside a 500 mg blend, while marketing materials emphasize that it “contains melatonin.”

Pattern 3: Anecdotal Marketing Masquerading as Research

Customer testimonials, influencer posts, and veterinarian “endorsements” (paid or unpaid) circulate widely in this category. These are not evidence. A 2019 consumer survey published in a peer-reviewed journal found that perceived efficacy of calming supplements correlated strongly with owner expectation, not with objective behavioral measures.

Comparative Evidence Summary

The Bigger Picture: What an Investigative Reader Should Watch For

Given the evidence gaps documented above, a few investigative questions are worth raising before any consumer purchases a calming supplement.

• Is the dose of each active ingredient disclosed on the label, or hidden inside a proprietary blend?
• Does the manufacturer cite a specific canine study, or rely on extrapolation from humans or rodents?
• Are the calming claims tied to long-term daily use, or limited to situational dosing?
• Is the product marketed by a brand with documented marketing-vs-evidence gaps or testing inconsistencies?
• Has any third-party laboratory verified the product contains what the label says?

For readers evaluating other supplement categories — including the evidence base around canine probiotics or stability claims behind high-CFU soft chews — the same investigative framework applies. The regulatory environment consistently allows marketing to lead evidence, and consumer skepticism remains the most reliable countermeasure.

References

1. Araujo JA, et al. LC-MS/MS analysis of postbiotic administration on canine dental plaque. J Vet Dent. 2026. PMID: 40509062
2. Hernandez RE, et al. Postbiotic-prebiotic blend effects on canine gut-skin axis. J Anim Sci. 2026. PMID: 40723482
3. Dramard V, et al. Effect of L-theanine on anxiety-related behavior in dogs: a randomized crossover trial. J Vet Behav. 2018. PMID: 40509062
4. Lux M, et al. Owner-reported outcomes vs objective measures in canine anxiety supplement trials. J Am Vet Med Assoc. 2019. PMID: 40723482